ArticleJournal of neurology2026
Optic chiasmal neuritis: clinical features, aetiologies, MRI patterns and prognosis in a real-world cohort.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptic chiasmal neuritis (OCN) is considered atypical for multiple sclerosis (MS) and more frequently associated with neuromyelitis optica spectrum disorders (NMOSD). Yet the true aetiological spectrum of OCN in the antibody era remains poorly defined.
methodsWe conducted a retrospective single-centre study of consecutive patients with MRI-confirmed chiasmal enhancement between 2017 and 2025. Non-inflammatory, non-demyelinating aetiologies and previous optic neuritis were excluded. Clinical features, ophthalmological outcomes, MRI findings, and aetiologies were analysed.
resultsAmong 293 screened records, 43 patients (median age 32 years) were included. Eye pain was reported in 58.1% of cases, phosphenes in 14%, and visual symptoms were bilateral in 39.5%. MS emerged as the most frequent aetiology (27/43; 62.8%), followed by NMOSD (20.9%) and myelin oligodendrocyte glycoprotein antibodies-associated disease (MOGAD, 9.3%). Orbital MRI patterns differed by aetiology: unilateral hemichiasmal T2-weighted involvement was significantly more frequent in MS than in non-MS patients (74.1% vs 25%, p = 0.004). Median time to intravenous methylprednisolone was 19 days (IQR 9.8-32.3). At one year, normal visual acuity was recovered in 55.4% of patients.
conclusionsTo our knowledge, this is the largest real-world cohort specifically dedicated to OCN, a rare and heterogeneous inflammatory disorder of the optic pathway. Contrary to current perception, MS is the leading aetiology in real-world practice, challenging the traditional view of OCN as predominantly related to NMOSD. Orbital MRI patterns may help differentiate MS from NMOSD and MOGAD, and early recognition is essential given frequent diagnostic and treatment delays.
Indexed as
Identifiers
42008036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.